title: Efficacy of a new spot-on formulation of selamectin plus sarolaner against four common tick species infesting cats in Europe.
abstract: A single application of a new spot-on formulation of selamectin plus sarolaner (Stronghold®Plus, Zoetis) was evaluated for efficacy against the most common tick species infesting cats in Europe. In each of the seven laboratory studies, 16 adult and purpose-bred cats were randomly allocated to one of two treatment groups based on pre-treatment tick counts. Weekly infestations with 50 unfed adult Ixodes ricinus (2 studies), Ixodes hexagonus (1 study), Dermacentor reticulatus (2 studies), or Rhipicephalus sanguineus (2 studies) were scheduled on Days -2, 5, 12, 19, 26 and 33. Cats were treated on Day 0 with the spot-on formulation at the minimum recommended label dose of 6.0mg selamectin and 1.0mg sarolaner per kg bodyweight or with a placebo. Ticks were counted 48h after treatment and after each re-infestation. No treatment-related adverse reactions were recorded in any of the studies. Geometric mean live tick counts were significantly (P≤0.0012) lower in the selamectin/sarolaner-treated group compared to the placebo-treated group at all time-points. Against I. ricinus and I. hexagonus, efficacy was ≥97.2% against existing infestations and ≥97.4% against weekly re-infestations for at least 5 weeks. Treatment was 100% effective against existing R. sanguineus infestations and was ≥95.8% for at least 4 weeks. Against D. reticulatus treatment resulted in ≥94.4% efficacy for at least 4 weeks. Thus, a single application of the new spot-on formulation of selamectin plus sarolaner at the minimum dose provides rapid treatment of existing infestations and is at least one month effective against re-infestation by all relevant European tick species in cats.
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, B-1930 Zaventem, Belgium. Electronic address: thomas.geurden@zoetis.com.
authors.forename: Thomas
authors.initials: T
authors.lastname: Geurden
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, B-1930 Zaventem, Belgium.
authors.forename: Csilla
authors.initials: C
authors.lastname: Becskei
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007 USA.
authors.forename: Adriano F
authors.initials: AF
authors.lastname: Vatta
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, B-1930 Zaventem, Belgium.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Slootmans
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007 USA.
authors.forename: Marcela
authors.initials: M
authors.lastname: von Reitzenstein
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007 USA.
authors.forename: Vickie L
authors.initials: VL
authors.lastname: King
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, B-1930 Zaventem, Belgium.
authors.forename: Dan
authors.initials: D
authors.lastname: Lin
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007 USA.
authors.forename: Douglas
authors.initials: D
authors.lastname: Rugg
mesh_terms: D056810:Acaricides / Q000008:administration & dosage*; D000287:Administration, Topical; D000818:Animals; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D005060:Europe; D005260:Female; D007555:Isoxazoles / Q000008:administration & dosage*; D007559:Ivermectin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008297:Male; D011897:Random Allocation; D013983:Tick Control / Q000592:standards*; D013984:Tick Infestations / Q000188:drug therapy / Q000662:veterinary*; D013987:Ticks; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D056810:Acaricides; D007555:Isoxazoles; D007559:Ivermectin; C414354:selamectin
keywords: Cat; Dermacentor reticulatus; Dose confirmation; Isoxazoline; Sarolaner; Selamectin; Tick; Topical